Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 38-47

  Semelakova M ^a   Jendzelovsky R ^a   Fedorocko P ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Aristoforin; CYP3A4; Drug efflux; Drug resistance; Hyperforin; Hypericin

Indexed keywords

ABC TRANSPORTER; ARISTOFORIN; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYTOCHROME P450 3A4; HYPERFORIN; HYPERICIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN; PHOTOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; LUCIFERIN; PERYLENE; PHLOROGLUCINOL; TERPENE; TUMOR PROTEIN;

ARTICLE; CARCINOMA CELL; CELL MEMBRANE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; HUMAN CELL; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COLON TUMOR; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; INTRACELLULAR SPACE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; BLOTTING, WESTERN; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOCHROME P-450 CYP3A; FIREFLY LUCIFERIN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SPACE; MEMBRANE TRANSPORT PROTEINS; NEOPLASM PROTEINS; PERYLENE; PHLOROGLUCINOL; REAL-TIME POLYMERASE CHAIN REACTION; TERPENES;

EID: 84962692886     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.03.045     Document Type: Article

References (41)

1. Šemeláková M., Mikeš J., Jendželovský R., Fedoročko P. The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells. J. Photochem. Photobiol. B: Biol. 2012, 117:115-125.
2. Agostinis P., Assefa Z., Vantieghem A., Vandenheede J.R., Merlevede W., De Witte P. Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv. Enzyme Regul. 2000, 40:157-182.
3. Sacková V., Fedorocko P., Szilárdiová B., Mikes J., Kleban J. Hypericin-induced photocytotoxicity is connected with G2/M arrest in HT-29 and S-phase arrest in U937 cells. Photochem. Photobiol. 2006, 82:1285-1291.
4. Mikes J., Kleban J., Sacková V., Horváth V., Jamborová E., Vaculová A., Kozubík A., Hofmanová J., Fedorocko P. Necrosis predominates in the cell death of human colon adenocarcinoma HT-29 cells treated under variable conditions of photodynamic therapy with hypericin. Photochem. Photobiol. Sci. 2007, 6:758-766.
5. Süloğlu A.K., Selmanoğlu G., Akay M.T. Alterations in dysadherin expression and F-actin reorganization: a possible mechanism of hypericin-mediated photodynamic therapy in colon adenocarcinoma cells. Cytotechnology 2015, 67:311-330.
6. Kamuhabwa A., Agostinis P., Ahmed B., Landuyt W., van Cleynenbreugel B., van Poppel H., de Witte P. Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem. Photobiol. Sci. 2004, 3:772-780.
7. Sanovic R., Verwanger T., Hartl A., Krammer B. Low dose hypericin-pDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagnosis Photodyn. Ther. 2011, 8:291-296.
8. Erdelmeier C.A. Hyperforin possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998, 31:2-6.
9. Gartner M., Muller T., Simon J.C., Giannis A., Sleeman J.P. Aristoforin a novel stable derivative of hyperforin, is a potent anticancer agent. Chembiochem 2005, 6:171-177.
10. Eisenblätter T., Hüwel S., Galla H.J. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier. Brain Res. 2003, 971:221-231.
11. Watkins R.E., Maglich J.M., Moore L.B., Wisely G.B., Noble S.M., Davis-Searles P.R., Lambert M.H., Kliewer S.A., Redinbo M.R. A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003, 42:1430-1438.
12. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001, 11:1156-1166.
13. Wang E.J., Barecki-Roach M., Johnson W.W. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin. Pharm. Pharmacol. 2004, 56:123-128.
14. Komoroski B.J., Zhang S., Cai H., Hutzler J.M., Frye R., Tracy T.S., Strom S.C., Lehmann T., Ang C.Y.W., Cui Y.Yan, Venkataramanan R. Induction and inhibition of cytochromes p450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metabol. Disp. 2004, 32:512-518.
15. Obach R.S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 2000, 294:88-95.
16. Cui Y., Ang C.Y., Beger R.D., Heinze T.M., Hu L., Leakey J. In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab. Dispos. 2004, 32:28-34.
17. Jendželovská Z., Jendželovský R., Hiľovská L., Kovaľ J., Mikeš J., Fedoročko P. Single pre-treatment with hypericin a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. Toxicol. In Vitro 2014, 28:1259-1273.
18. Haas C.E., Brazeau Ć.D., Cloen Ć.D., Booker B.M., Frerichs Ć.V., Zaranek Ć.C., Frye R.F., Kufel Ć.T. Cytochrome P450 mRNA expression. Eur. J. Clin. Pharmacol. 2005, 61:583-593.
19. Greuet J., et al. Biochem. Biophys. Res. Commun. 1996, 225:689.
20. Flockhart D.A. Drug Interactions: Cytochrome P 2007, http://medicine.iupui.edu/clinpharm/ddis/table.asp.
21. Zhang A.Y., Elmets C.A. Drug-induced photosensitivity. Medscape 2014, 16:325-332.
22. Jendzelovsky R., Mikes J., Koval J., Soucek K., Prochazkova J., Kello M., Sackova V., Hofmanova J., Kozubik A., Fedorocko P. Drug efflux transporters MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem. Photobiol. Sci. 2009, 8:1716-1723.
23. Olivo M., Du H.Y., Bay B.H. Hypericin lights up the way for the potential treatment of nasopharyngeal cancer by photodynamic therapy. Curr. Clin. Pharmacol. 2006, 1:217-222.
24. Hostanska K., Reichling J., Bommer S., Weber M., Saller R. Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro. Pharmazie 2002, 57:323-331.
25. Meinke M.C., Schanzer S., Haag S.F., Casetti F., Müller M.L., Wölfle U., Kleemann A., Lademann J., Schempp C.M. In vivo photoprotective and anti-inflammatory effect of hyperforin is associated with high antioxidant activity in vitro and ex vivo. Eur. J. Pharm. Biopharm. 2012, 81:346-350.
26. Ševčovičová A., Šemeláková M., Plšíková J., Loderer D., Imreová P., Gálová E., Kožurková M., Miadoková E., Fedoročko P. DNA-protective activities of hyperforin and aristoforin. Toxicol. In Vitro 2015, 29:631-637.
27. Vogel Ch., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2013, 13:227-232.
28. Kapushesky M. Gene Expression Atlas update - a value added database of microarray and sequencing-based functional genomics experiments. Nucleic Acids Res. 2012, 40:1077-1081.
29. Longley D.B., Johnston P.G. Molecular mechanisms of drug resistance. J. Pathol. 2005, 205:275-292.
30. Goldman B. Multidrug resistance: can new drugs help chemotherapy score against cancer?. J. Natl. Cancer. Inst. 2003, 95:255-257.
31. Rimet O., Mirrione A., Barra Y. Multidrug-resistant phenotype influences the differentiation of a human colon carcinoma cell line. Biochem. Biophys. Res. Commun. 1999, 259:43-49.
32. Gómez-Martínez A., García-Morales P., Carrato Alfredo, Castro-Galache M.D., Soto J.L., Carrasco-García E., García-Bautista M., Guaraz P., Ferragut J.A., Saceda M. Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol. Cancer Res. 2007, 5:641-653.
33. Gutmann H., Hruz P., Zimmermann C., Beglinger C., Drewe J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 2005, 70:695-699.
34. Xie R., Tan L.H., Polasek E.C., Hong C., Teillol-Foo M., Gordi T., Sharma A., Nickens D.J., Arakawa T., Knuth D.W., Antal E.J. J. Clin. Pharmacol. 2005, 45:352-356.
35. Huttunen K.M., Mahonen N., Raunio H., Rautio J. Cytochrome P450-activated prodrugs: targeted drug delivery. Curr. Med. Chem. 2008, 15:2346-2365.
36. Oyama T., Kagawa N., Kunugita N., Kitagawa K., Ogawa M., Yamaguchi T., Suzuki R., Kinaga T., Yashima Y., Ozaki S., Isse T., Kim Y.D., Kim H., Kawamoto T. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 2004, 9:1967-1976.
37. McFadyen M.C., Melvin W.T., Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol. Cancer Ther. 2004, 3:363-371.
38. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
39. Basseville A., Preisser L., de Carné Trécesson S., Boisdron-Celle M., Gamelin E., Coqueret O., Morel A. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol. Cancer 2011, 10:80-92.
40. Rodriguez-Antona C., Leskela S., Zajac M., Cuadros M., Alves J., Moneo M.V., Martín C., Cigudosa J.C., Carnero A., Robledo M., Benitez J., Martinez-Delgado B. Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood 2007, 110:3345-3351.
41. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.